Logo image of TRIB

TRINITY BIOTECH PLC-SPON ADR (TRIB) Stock Fundamental Analysis

USA - NASDAQ:TRIB - US8964385046 - ADR

1.02 USD
-0.08 (-7.27%)
Last: 10/16/2025, 6:04:05 PM
1.05 USD
+0.03 (+2.94%)
After Hours: 10/16/2025, 6:04:05 PM
Fundamental Rating

2

Taking everything into account, TRIB scores 2 out of 10 in our fundamental rating. TRIB was compared to 191 industry peers in the Health Care Equipment & Supplies industry. TRIB may be in some trouble as it scores bad on both profitability and health. TRIB is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year TRIB has reported negative net income.
TRIB had a negative operating cash flow in the past year.
TRIB had negative earnings in 4 of the past 5 years.
In multiple years TRIB reported negative operating cash flow during the last 5 years.
TRIB Yearly Net Income VS EBIT VS OCF VS FCFTRIB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M -80M -100M

1.2 Ratios

TRIB has a Return On Assets (-30.78%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -30.78%
ROE N/A
ROIC N/A
ROA(3y)-38.57%
ROA(5y)-23.97%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TRIB Yearly ROA, ROE, ROICTRIB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K 1.5K

1.3 Margins

Looking at the Gross Margin, with a value of 34.83%, TRIB is doing worse than 72.25% of the companies in the same industry.
TRIB's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for TRIB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 34.83%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.46%
GM growth 5Y-3.74%
TRIB Yearly Profit, Operating, Gross MarginsTRIB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100

More info and screens

1

2. Health

2.1 Basic Checks

TRIB does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TRIB has about the same amount of shares outstanding.
TRIB has more shares outstanding than it did 5 years ago.
TRIB has a better debt/assets ratio than last year.
TRIB Yearly Shares OutstandingTRIB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M
TRIB Yearly Total Debt VS Total AssetsTRIB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

TRIB has an Altman-Z score of -0.85. This is a bad value and indicates that TRIB is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of TRIB (-0.85) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -0.85
ROIC/WACCN/A
WACC7.52%
TRIB Yearly LT Debt VS Equity VS FCFTRIB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M

2.3 Liquidity

TRIB has a Current Ratio of 1.28. This is a normal value and indicates that TRIB is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.28, TRIB is not doing good in the industry: 79.58% of the companies in the same industry are doing better.
TRIB has a Quick Ratio of 1.28. This is a bad value and indicates that TRIB is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.68, TRIB is not doing good in the industry: 88.48% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.28
Quick Ratio 0.68
TRIB Yearly Current Assets VS Current LiabilitesTRIB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 16.67% over the past year.
Looking at the last year, TRIB shows a quite strong growth in Revenue. The Revenue has grown by 8.31% in the last year.
Measured over the past years, TRIB shows a decrease in Revenue. The Revenue has been decreasing by -7.41% on average per year.
EPS 1Y (TTM)16.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16%
Revenue 1Y (TTM)8.31%
Revenue growth 3Y-8.8%
Revenue growth 5Y-7.41%
Sales Q2Q%18.09%

3.2 Future

The Earnings Per Share is expected to grow by 34.68% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 11.62% on average over the next years. This is quite good.
EPS Next Y65.8%
EPS Next 2Y34.68%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year10.13%
Revenue Next 2Y11.62%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
TRIB Yearly Revenue VS EstimatesTRIB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M 100M
TRIB Yearly EPS VS EstimatesTRIB Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 -5 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

TRIB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TRIB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TRIB Price Earnings VS Forward Price EarningsTRIB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TRIB Per share dataTRIB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

TRIB's earnings are expected to grow with 34.68% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.68%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

TRIB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TRINITY BIOTECH PLC-SPON ADR

NASDAQ:TRIB (10/16/2025, 6:04:05 PM)

After market: 1.05 +0.03 (+2.94%)

1.02

-0.08 (-7.27%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-13 2025-08-13/bmo
Earnings (Next)04-03 2026-04-03/bmo
Inst Owners0.87%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap19.58M
Analysts85.71
Price TargetN/A
Short Float %N/A
Short Ratio0.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-128.03%
Min EPS beat(2)-272.55%
Max EPS beat(2)16.49%
EPS beat(4)1
Avg EPS beat(4)-116.51%
Min EPS beat(4)-272.55%
Max EPS beat(4)16.49%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-7.88%
Min Revenue beat(2)-9.97%
Max Revenue beat(2)-5.78%
Revenue beat(4)0
Avg Revenue beat(4)-6.76%
Min Revenue beat(4)-9.97%
Max Revenue beat(4)-1.38%
Revenue beat(8)1
Avg Revenue beat(8)-7.57%
Revenue beat(12)1
Avg Revenue beat(12)-11.44%
Revenue beat(16)3
Avg Revenue beat(16)-13.23%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.32
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.68
EYN/A
EPS(NY)-0.92
Fwd EYN/A
FCF(TTM)-0.74
FCFYN/A
OCF(TTM)-0.22
OCFYN/A
SpS3.21
BVpS-1.83
TBVpS-4.51
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -30.78%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 34.83%
FCFM N/A
ROA(3y)-38.57%
ROA(5y)-23.97%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.46%
GM growth 5Y-3.74%
F-Score4
Asset Turnover0.6
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 539.63%
Cap/Sales 16.35%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.28
Quick Ratio 0.68
Altman-Z -0.85
F-Score4
WACC7.52%
ROIC/WACCN/A
Cap/Depr(3y)316%
Cap/Depr(5y)319.23%
Cap/Sales(3y)10.22%
Cap/Sales(5y)10.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16%
EPS Next Y65.8%
EPS Next 2Y34.68%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)8.31%
Revenue growth 3Y-8.8%
Revenue growth 5Y-7.41%
Sales Q2Q%18.09%
Revenue Next Year10.13%
Revenue Next 2Y11.62%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-12.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y0.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y63.74%
OCF growth 3YN/A
OCF growth 5YN/A